WuXi PharmaTech begins construction of R&D and cGMP manufacturing campus

Published: 9-May-2014
Manufacturing

The plant in Changzhou, China will be operational in fourth quarter next year


WuXi PharmaTech, a pharmaceutical, biotechnology and medical device research and development (R&D) services company with operations in China and the US, is building a new manufacturing plant in Changzhou, China.

The company says its manufacturing subsidiary, Syn-The-All (STA) Pharmaceuticals, has begun construction of the R&D and cGMP manufacturing plant with the aim of meeting growing demand for WuXi's manufacturing services, which have quadrupled their revenues in the past four years.

The new campus will be constructed in phases and include both research manufacturing and commercial manufacturing facilities. Facilities constructed in phase 1 will double the company's current manufacturing capacity and be operational by the fourth quarter of 2015. Upon completion of the entire project, the site will triple current capacity and could support more than 1,500 employees, who will take new chemical entities from early stage process development through preclinical and clinical deliveries to commercial production.

'This project marks an important milestone in STA's mission of building a fully integrated API development and manufacturing platform,' said Ge Li, Chairman and CEO of WuXi PharmaTech. 'It furthers our commitment to providing partners worldwide with highly efficient and cost-effective solutions that help bring better medicines faster to patients.'

See more

You may also like

Manufacturing

Advancing targeted protein degraders: leveraging CMC strategies for rapid IND submission and bioavailability solutions

Read more
In the rapidly evolving pharmaceutical landscape, targeted protein degraders (TPDs) represent a significant leap forward. TPDs offer a novel therapeutic modality with the potential to address disease-causing proteins that have traditionally been difficult to target with conventional small molecules

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Abselion launches AAVX and AAV9 Total Capsid Quantification Kits Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes
  3. diaago and Peak Analysis & Automation partner to bring practical automation solutions to research laboratories Using diaago's customer-first approach with PAA’s decades of expertise in laboratory robotics, the collaboration promises to deliver solutions to streamline workflows, boost throughput and reduce bottlenecks
  4. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Advancing targeted protein degraders: leveraging CMC strategies for rapid IND submission and bioavailability solutions

In the rapidly evolving pharmaceutical landscape, targeted protein degraders (TPDs) represent a significant leap forward. TPDs offer a novel therapeutic modality with the potential to address disease-causing proteins that have traditionally been difficult to target with conventional small molecules
Manufacturing

WuXi AppTec peptide facility receives PMDA approval

The company's Changzhou oligonucleotide API manufacturing site was approved by Japan's Pharmaceuticals and Medical Devices Agency
Manufacturing

WuXi AppTec triples peptide manufacturing capacity and launches the new Taixing API manufacturing site

Expansion boosts solid-phase peptide synthesis total reactor volume to 32,000 L in response to surging demand
Manufacturing

AtkinsRéalis awarded engineering design services contract for API manufacturing facility in Singapore

When completed, the Singapore site will play a critical role in WuXi AppTec’s global network across Asia, Europe and North America, meeting the growing demand from multinational customers and strengthening collaborations with a wide range of partners
Manufacturing

WuXi debuts high potency sterile injectable manufacturing line

The new HP injectable manufacturing line, with an annual capacity of 12 million units, further enhances the company’s manufacturing capabilities
Manufacturing

WuXi STA adds L reactors at Changzhou campus

The total reactor volume of the Solid Phase Peptide Synthesisers (SPPS) at WuXi TIDES has increased to over 10,000 L
Manufacturing

Wuxi STA's continuous manufacturing line under operation

This new CM line provides global customers an enhanced oral drug development solution, enabling higher yields and shortened timelines to market
Subscribe now